# Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

> **NCT05760612** · PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 300 (estimated)

## Conditions studied

- Early-stage Breast Cancer
- HER2-positive Breast Cancer
- Adjuvant Treatment After Trastuzumab
- RCB Classification 1-2
- Neratini

## Interventions

- **DRUG:** Trastuzumab and neratinib
- **DRUG:** Trastuzumab and Pertuzumab

## Key facts

- **NCT ID:** NCT05760612
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-14
- **Primary completion:** 2028-02-16
- **Final completion:** 2028-11-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760612, "Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05760612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*